via chain scission according to the kinetic law (with k being the average rate constant for chain scission):
Mn = Mn,o x e -kt
The short second phase starts at a specific chain length and is characterised by the onset of volume and total mass loss via bioresorption. Unlike other degradable dermal fillers, the non-toxic oligomers resulting from total bioresorption of the Ellansé microspheres are completely excreted through normal metabolic pathways. This is the basis for the unique Ellansé dermal filler Family, differentiated only by the initial polymer chain length, offering tunable longevity. This has led to the creation of
the new and innovative products in the Ellansé Family, with clinical efficacy of 1, 2, 3, or 4 years, respectively.
Conclusions Superior to other dermal fillers,
Ellansé™, now available in over 60
countries worldwide, offers a unique combination of total and predictable bioresorbability and sustained performance for its entire Family, which is clinically proven.
Ellansé is an injectable
bioresorbable implant, indicated for deep dermal and subdermal implantation. It is a first in its class, next generation, biostimulatory dermal filler for patients who are not satisfied with the cost and inconvenience associated with frequent repetitive treatments for the same indication. Ellansé offers the maximum
potential for modelling and lifting owing to the combination of optimum viscosity, unique elasticity and uniform homogeneity. Furthermore, its three unique and technologically advanced features of sustained performance, tunable longevity and total bioresorbability (STAT Technology™), successfully overcome some of the significant shortcomings in the dermal filler arena and optimise many characteristics required in an ‘ideal dermal filler’. Ellansé-S (1 year), Ellansé-M (2 years), Ellansé-L (3 years) and
Ellansé dermal filler family longevity options The Ellans• Key Features
■ Safety: PCL used in CE and US FDA approved medical devices for over 20 years
■ Bio-stimulatory dermal filler: strong presence of type I collagen
■ Fully bioresorbable: proven through radio-labelling studies
■ Sustained performance: maintained clinical effect ■ Tunable longevity: choice for both physician and patient
■ Cost-effective: for physician and patient
Ellansé-E (4 years) are specifically designed as a total customised solution for facial soft tissue augmentation, and can be used for a variety of indications. Patients
looking for longer-lasting and sustained results will benefit from Ellansé, creating customer satisfaction, leading to a higher patient retention rate.
prime-journal.com | Product Portfolio
❚
25
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76